United Therapeutics Corporation Adjustments to Additional Paid in Capital, Equity Component of Convertible Debt
United Therapeutics Corporation (UTHR) reported Adjustments to Additional Paid in Capital, Equity Component of Convertible Debt of $10.80 million for the 12-month period ending 2019-12-31, per its 10-K filed 2021-02-24.
Discontinued › Shareholders' Equity
us-gaap:AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt · last filed 2021-02-24
- United Therapeutics Corporation adjustments to additional paid in capital, equity component of convertible debt for the quarter ending 2019-12-31 was $0.00.
- United Therapeutics Corporation adjustments to additional paid in capital, equity component of convertible debt for the quarter ending 2019-09-30 was $0.00.
- United Therapeutics Corporation adjustments to additional paid in capital, equity component of convertible debt for the quarter ending 2019-06-30 was $10.80M.
- United Therapeutics Corporation adjustments to additional paid in capital, equity component of convertible debt for fiscal 2019 was $10.80M.
- United Therapeutics Corporation adjustments to additional paid in capital, equity component of convertible debt for fiscal 2011 was $56.19M.
| Period end | Adjustments to Additional Paid in Capital, Equity Component of Convertible Debt 3 month | Adjustments to Additional Paid in Capital, Equity Component of Convertible Debt 6 month | Adjustments to Additional Paid in Capital, Equity Component of Convertible Debt 9 month | Adjustments to Additional Paid in Capital, Equity Component of Convertible Debt 12 month |
|---|---|---|---|---|
| 2019-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2021-02-24 | $0.00 derived: sum of 2 quarters · filed 2021-02-24 | $10.80M derived: sum of 3 quarters · filed 2021-02-24 | $10.80M 10-K · filed 2021-02-24 |
| 2019-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2020-10-28 | $10.80M derived: sum of 2 quarters · filed 2020-10-28 | $10.80M 10-Q · filed 2020-10-28 | |
| 2019-06-30 | $10.80M 10-Q · filed 2020-07-29 | $10.80M 10-Q · filed 2020-07-29 | ||
| 2011-12-31 | $56.19M 10-K · filed 2014-02-25 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Viatris Inc (VTRS) | United States | $20.008B | -0.00 |
| Royalty Pharma plc (RPRX) | United States | $22.628B | |
| Jazz Pharmaceuticals plc (JAZZ) | $15.333B | 16.07 | |
| Roivant Sciences Ltd. (ROIV) | $26.105B | -96.08 | |
| INSMED Inc (INSM) | United States | $26.566B | -26.60 |
| Summit Therapeutics Inc. (SMMT) | United States | $13.071B | -13.21 |
| BridgeBio Pharma, Inc. (BBIO) | United States | $12.947B | -20.72 |
| CORCEPT THERAPEUTICS INC (CORT) | United States | $12.804B | 169.10 |
| BIOMARIN PHARMACEUTICAL INC (BMRN) | United States | $11.879B | 151.80 |
| MADRIGAL PHARMACEUTICALS, INC. (MDGL) | United States | $11.859B | -38.17 |